About this Research Topic
The most common drug-resistant strains are MRSA (methicillin-resistant S. aureus); however, resistance to many other drug groups has frequently occurred. These include glycopeptides (e.g., vancomycin and teicoplanin), oxazolidinones (like linezolid), macrolides, lincosamides, ketolides, streptogramins B, fluoroquinolones (ciprofloxacin), aminoglycosides (gentamycin, tobramycin), tetracyclines, mupirocin, fusidic acid and daptomycin. The development of alternative treatments for antibiotic-resistant S. aureus is still progressing, and nanoparticles, quorum sensing inhibition, iron chelation, or phage therapy are being considered. S. aureus exhibits relatively high virulence and broad plasticity to adapt to new environments. Since the mortality rate of resistant staphylococcal infections reaches 50%, the search for new drugs and therapies is urgently needed.
This Research Topic aims to investigate new potential therapies for treating infections caused by antibiotic-resistant S. aureus strains, such as novel antibacterial substances, procedures to combat the disease, or the evaluation of synergistic activity of new compounds and antibiotics. In this Topic, we welcome the submission of Original Research articles, Mini-Reviews, Clinical Trials, Case Reports, and Brief Research Reports that deal with the issue of drug-resistant S. aureus and new potential treatments.
Keywords: MRSA, VRSA, antibiotics, antibacterial drugs, multidrug resistance, novel drugs
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.